Evotec SE
Company Profile
Business description
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
Contact
Essener Bogen 7
Manfred Eigen Campus
Hamburg22419
DEUT: +49 40560810
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
4,766
Stocks News & Analysis
stocks
Nvidia: Collaboration with Intel might bring some goodwill with the US
stocks
What now for Santos after takeover offer collapses?
stocks
Morningstar initiates coverage on small cap ASX REIT
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,061.20 | 20.50 | -0.23% |
CAC 40 | 7,853.59 | 1.02 | -0.01% |
DAX 40 | 23,639.41 | 35.12 | -0.15% |
Dow JONES (US) | 46,315.27 | 172.85 | 0.37% |
FTSE 100 | 9,216.67 | 11.44 | -0.12% |
HKSE | 26,545.10 | 0.25 | 0.00% |
NASDAQ | 22,631.48 | 160.75 | 0.72% |
Nikkei 225 | 45,045.81 | 257.62 | -0.57% |
NZX 50 Index | 13,231.66 | 111.63 | 0.85% |
S&P 500 | 6,664.36 | 32.40 | 0.49% |
S&P/ASX 200 | 8,773.50 | 18.70 | -0.21% |
SSE Composite Index | 3,820.09 | 11.57 | -0.30% |